Evidence map›Paper›PMID 41948340›Full record

ReviewFrontiers in immunology2026

MicroRNAs in thyroid eye disease: expression signatures and clinical implications.

Xinyu Wang, Hongyue Chen, Songwei Li

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinyu WangThe Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Hongyue ChenThe Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Songwei LiThe Department of Rheumatology ,The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid eye disease (TED), also known as Graves' ophthalmopathy (GO) or thyroid-associated ophthalmopathy (TAO), is an autoimmune orbital disease. The core pathogenic mechanism is immune dysregulation triggered by self-antigens, which activates orbital fibroblasts and leads to pathological changes such as tissue hyperplasia and fibrosis. The clinical manifestations include proptosis and eyelid retraction. MicroRNA (miRNA), as a key factor in post-transcriptional regulation, is widely involved in the occurrence and development of TED. Altered expression profiles of specific miRNAs, such as miR-21, miR-146a, and miR-144-3p, have been observed in clinical samples and

Indexed as

Graves OphthalmopathyMicroRNAsAnimalsFibroblastsGene Expression ProfilingGene Expression RegulationHumansMicroRNAsGOmiRNApathogenic mechanismTAOTEDtherapeutic prospects

Identifiers

PMID41948340
PMCPMC13050856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.